Disclosed Sponsored Editorial in Health and Food Titles

Model the link as worth zero. Every placement bought here carries rel=sponsored, which is what Google's link spam policy requires of any link paid for in money or product, and we brief your team to forecast it that way from the first meeting. What you are buying is the readership of a title your buyer already trusts, a disclosed piece of writing good enough that the editor would have wanted it anyway, and a URL you can cite in a sales deck for years. What the money actually buys: Distribution to a defined audience: a dietitian trade title read by the people who recommend your product, a food and beverage industry publication read by category buyers, a condition-specific site read by patients at the moment of decision. We look at the newsletter list, the comment activity, the social reshare pattern of the last ten features, and the presence of a real audience rather than a traffic estimate from a third-party tool. Disclosure, and why we will not soften it: The disclosure runs above the article, in the reader's line of sight, in plain words. Not a grey line in the footer, not the word partner used as a euphemism. The FTC's endorsement guides, revised in 2023, treat a disclosure a reader misses as no disclosure, and in health and food the enforcement history is long enough that this is not a theoretical position. If a publisher offers to bury it, we withdraw the placement and tell you why. The writing: We write it. Sponsored placements fail because they read like a brochure that wandered into a magazine, and the fix is not more brand mentions but a piece with an actual argument in it: a reformulation problem and how it was solved, what a clinical trial protocol did and did not test, why a supply chain decision changed a label. The product appears where it belongs in that argument and nowhere else. If the subject cannot carry a piece without three forced product mentions, the subject is wrong and we will say so before you pay a placement fee. Claims review: Every draft in a regulated category goes to your medical, legal and regulatory reviewers before it reaches the publisher, and we write to survive that review rather than negotiating it afterwards. For supplement clients that means structure-function language and the DSHEA disclaimer where it applies. For medtech it means indications-for-use language that matches the cleared labelling. We would rather lose a headline in review than have a live page you have to pull. What is not in scope: No follow links. No negotiating an undisclosed placement, whatever the publisher's own house practice is. No advertorial networks that resell the same slot across forty sites. No paying a publication that will not name its editor. And no promise about ranking movement, because a rel=sponsored link should not produce any, and if someone is selling you one that does, they are selling you a link Google's policy tells it to ignore. Not for you if: Your objective is domain authority. Buy nothing here; spend the budget on digital PR or on the product page that is failing to convert the traffic you already have. This is also wrong for you if the legal team's position is that disclosure dilutes the message. That position is not compatible with running paid editorial in health or food, and no agency can make it compatible. Reporting: You receive the live URL, the disclosure as rendered on desktop and mobile, the rel attributes, the publisher's own audience figures with the date they were supplied, and referral sessions and assisted conversions from the placement over the following ninety days.